Short Interest in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Decreases By 56.9%

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 65,500 shares, a drop of 56.9% from the February 29th total of 152,000 shares. Based on an average daily trading volume, of 789,500 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.5% of the company’s stock are short sold.

60 Degrees Pharmaceuticals Trading Down 0.8 %

60 Degrees Pharmaceuticals stock traded down $0.00 during mid-day trading on Thursday, hitting $0.26. 25,581 shares of the company’s stock traded hands, compared to its average volume of 348,995. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $8.65. The firm has a 50 day simple moving average of $0.34 and a two-hundred day simple moving average of $0.64.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in 60 Degrees Pharmaceuticals stock. Walleye Capital LLC purchased a new position in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 139,304 shares of the company’s stock, valued at approximately $103,000. Walleye Capital LLC owned 2.40% of 60 Degrees Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 7.96% of the stock is currently owned by hedge funds and other institutional investors.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.